Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing the treatment of GI diseases. Co. is focused on the development and commercialization of GI product opportunities. LINZESS® (linaclotide), Co.'s commercial product, is a product approved by the U.S. Food and Drug Administration in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation. Co. is also developing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis / bladder pain syndrome and endometriosis. The IRWD stock yearly return is shown above.
The yearly return on the IRWD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IRWD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|